Eicosanoid transcellular biosynthesis: From cell-cell interactions to in vivo tissue responses

被引:173
作者
Folco, Giancarlo
Murphy, Robert C.
机构
[1] Univ Colorado Denver, Dept Pharmacol, Hlth Sci Ctr, Aurora, CO 80045 USA
[2] Univ Milan, Ctr Cardiopulm Pharmacol, Milan, Italy
关键词
D O I
10.1124/pr.58.3.8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The biosynthesis of the biologically active metabolites of arachidonic acid involves a number of enzymes that are differentially expressed in cells. Prostaglandins and thromboxanes are derived from the chemically unstable prostaglandin (PG) H-2 intermediate synthesized by PGH synthases (cyclooxygenase-1/2) and leukotrienes from chemically unstable leukotriene A(4) by 5-lipoxygenase. Additional enzymes transform these reactive intermediates to a variety of chemical structures known collectively as the lipid mediators. Although some cells have the complete cassette of enzymes required for the production of biologically active prostaglandins and leukotrienes, the actual biosynthetic events often are a result of cell-cell interaction and a transfer of these chemically reactive intermediates, PGH(2) and leukotriene A(4), between cells. This process has come to be known as transcellular biosynthesis of eicosanoids and requires a donor cell to synthesize and release one component of the biosynthetic cascade and a second, accessory cell to take up that intermediate and process each into the final biologically active product. This review focuses on the evidence for transcellular biosynthetic events for prostaglandins, leukotrienes, and lipoxins occurring during cell-cell interactions. Evidence for arachidonic acid serving as a transcellular biosynthetic intermediate is presented. Experiments for transcellular events taking place in vivo that reveal the true complexity of eicosanoid biosynthesis within tissues are also reviewed.
引用
收藏
页码:375 / 388
页数:14
相关论文
共 57 条
[1]   ENHANCED EXCRETION OF URINARY LEUKOTRIENE-E(4) IN CORONARY-ARTERY DISEASE AND AFTER CORONARY-ARTERY BYPASS-SURGERY [J].
ALLEN, SP ;
SAMPSON, AP ;
PIPER, PJ ;
CHESTER, AH ;
OHRI, SK ;
YACOUB, MH .
CORONARY ARTERY DISEASE, 1993, 4 (10) :899-904
[2]  
Amat M, 1998, ARTHRITIS RHEUM, V41, P1645, DOI 10.1002/1529-0131(199809)41:9<1645::AID-ART16>3.0.CO
[3]  
2-Z
[4]   TIME-DEPENDENT UTILIZATION OF PLATELET ARACHIDONIC-ACID BY THE NEUTROPHIL IN FORMATION OF 5-LIPOXYGENASE PRODUCTS IN PLATELET-NEUTROPHIL CO-INCUBATIONS [J].
ANTOINE, C ;
MURPHY, RC ;
HENSON, PM ;
MACLOUF, J .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1128 (2-3) :139-146
[5]   Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles [J].
Barry, OP ;
Pratico, D ;
Lawson, JA ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (09) :2118-2127
[6]  
BIGBY TD, 1989, J IMMUNOL, V143, P1948
[7]   ADHESION PROMOTES TRANSCELLULAR LEUKOTRIENE BIOSYNTHESIS DURING NEUTROPHIL-GLOMERULAR ENDOTHELIAL-CELL INTERACTIONS - INHIBITION BY ANTIBODIES AGAINST CD18 AND L-SELECTIN [J].
BRADY, HR ;
SERHAN, CN .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (03) :1307-1314
[8]   ARTERIAL-WALLS GENERATE FROM PROSTAGLANDIN ENDOPEROXIDES A SUBSTANCE (PROSTAGLANDIN-X) WHICH RELAXES STRIPS OF MESENTERIC AND CELIAC ARTERIES AND INHIBITS PLATELET-AGGREGATION [J].
BUNTING, S ;
GRYGLEWSKI, R ;
MONCADA, S ;
VANE, JR .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 1976, 12 (06) :897-913
[9]   Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro [J].
Capra, V ;
Bolla, M ;
Belloni, PA ;
Mezzetti, M ;
Folco, GC ;
Nicosia, S ;
Rovati, GE .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (03) :590-598
[10]   INCREASED URINARY LEUKOTRIENE EXCRETION IN PATIENTS WITH CARDIAC ISCHEMIA - INVIVO EVIDENCE FOR 5-LIPOXYGENASE ACTIVATION [J].
CARRY, M ;
KORLEY, V ;
WILLERSON, JT ;
WEIGELT, L ;
FORDHUTCHINSON, AW ;
TAGARI, P .
CIRCULATION, 1992, 85 (01) :230-236